Serocorrelate of Protection Against GBS (PREPARE WP3)

PREPARE Work Package 3 -Development of a Serocorrelate of Protection Against GBS - Protocol Harmonisation.

A multicentre, international case-control study to develop a biobank of sera from 150 cases of serotype III GBS disease and associated clinical information from seven countries (Malawi, Uganda, UK, the Netherlands, Italy and France), with 3:1 (450) serotype matched healthy controls.

Study Overview

• Status: Recruiting
• Conditions: Group B Streptococcus Carrier in Childbirth; Group B Streptococcal Infection, Late-Onset; Group B Streptococcal Infection, Early-Onset; Group B Streptococcus Neonatal Sepsis; Group B Strep Infection

Detailed Description

Group B Streptococcus (GBS) causes severe infections in young infants across the world. In 2015 it was estimated that there were at least 319,000 infants under three months of age with GBS disease worldwide, resulting in 90,000 deaths and at least 10,000 children with long term disabilities. Around 20% of all pregnant women carry GBS in their vagina and bowel, and babies are exposed to GBS bacteria around the time of birth. The options for prevention are currently limited to offering antibiotics during labour.

A vaccine that could be given to pregnant women has the greatest potential to benefit mothers and babies worldwide. There are vaccines currently being tested in clinical trials, including in pregnant women. Given the complexity, size and costs associated with a phase III trial, it is generally agreed that indirect evidence (correlates) of protection (CoP), based on immunologic data from vaccine and seroepidemiological studies, opsonophagocytic assays and supported by animal models, could be pivotal for vaccine licensure, with effectiveness subsequently confirmed in post-licensure evaluations.

This study aims to develop a biobank of sera from 150 cases of serotype III GBS disease and associated clinical information from seven countries (Malawi, Uganda, UK, the Netherlands, Italy and France) with 3:1 (450) serotype matched healthy controls.

GBS cases will be identified through active surveillance of GBS disease in infants, as part of ongoing epidemiological studies in Uganda, the UK, Italy, France, the Netherlands and Malawi. Upon identification of cases, consent will be requested to obtain a serum sample (1-2 mL of blood collected from infant), the GBS isolate and to collect brief clinical and demographic details. Each site will aim to collect around 50 cases of invasive GBS disease cases (with all samples) over the course of 2 years.

Each site will also recruit approximately 1000 women to have a rectovaginal swab at 35-37 weeks gestation and cord and maternal blood samples at delivery. These women and their infants will be followed up to 90 days of age and considered appropriate controls if the infants are exposed to the same serotype/strain of GBS at delivery as the case - but do not develop GBS the first 90 days of life. We will select 3 controls for every case.

The biorepository will be established at the St George's University of London for all samples from the European Union and Malawi and the MRC/UVRI & LSHTM Uganda Research Unit for Ugandan samples.

• Study Type: Observational
• Enrollment (Estimated): 600

Contacts and Locations

• Study Contact: Name: Hannah Davies, Dr; Phone Number: +442087255214; Email: hdavies@sgul.ac.uk
• Study Contact Backup: Name: Madeleine Cochet; Phone Number: +442087255214; Email: mcochet@sgul.ac.uk

Study Locations

• France
  • Paris, France
    • Recruiting
    • Assistance Publique Hôpitaux de Paris (AP-HP)
    • Contact: Claire Poyart, Prof.; Phone Number: 01 58 41 15 60; Email: claire.poyart@aphp.fr
    • Contact: Asmaa Tazi; Phone Number: 015841156; Email: asmaa.tazi@aphp.fr
• Italy
  • Modena, Italy
    • Recruiting
    • Azienda Ospedaliero-Universitaria di Modena (AOU)
    • Contact: Alberto Berardi, Prof.; Email: Alberto.berardi@unimore.it
    • Contact: Tiziana Cassetti, Dr.; Phone Number: +393930413618; Email: tizianacassettibio@gmail.com
• Malawi
  • Blantyre, Malawi
    • Recruiting
    • Queen Elizabeth Central Hospital College of Medicine, P.O. Box 30096 Chichiri,
    • Contact: Maryke Nielsen, Dr.; Phone Number: +265 (0)1812423; Email: m.nielsen@liverpool.ac.uk
• Netherlands
  • Amsterdam, Netherlands
    • Recruiting
    • Academisch Medisch Centrum,Universiteit van Amsterdam
    • Contact: Merijn Bijlsma, Dr.; Email: m.bijlsma@amsterdamumc.nl
• Uganda
  • Kampala, Uganda
    • Recruiting
    • MUJHU - Makerere University Johns Hopkins University Research Collaboration/MUJHU Care Ltd
    • Principal Investigator: Musa Sekikubo, Dr
    • Contact: Mary Kyohere, Dr.; Email: mkyohere@mujhu.org
• United Kingdom
  • London, United Kingdom
    • Recruiting
    • St George's, University of London
    • Contact: Rakan Musleh; Email: rmusleh@sgul.ac.uk

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: No older than 2 months (Child)
• Accepts Healthy Volunteers: N/A

• Sampling Method: Non-Probability Sample

Study Population

The study will enroll infant subjects from the general population who are delivered at one of the six hospital sites.

Description

Inclusion Criteria:

Cases:

Infant 0-90 days of life with GBS identified from a normally sterile site.

Controls:

Healthy infant born to a GBS colonised woman that does not develop GBS disease between birth and 90 days of life.

Exclusion Criteria An infant is not eligible unless a parent/person with parental responsibility gives informed consent.

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Control
• Time Perspectives: Prospective

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
Cases; 150 infants with invasive serotype III GBS disease (isolation of GBS from a normally sterile site, i.e. blood or CSF) in the first 90 days of life from six countries (Malawi, Uganda, UK, the Netherlands, Italy and France).
Controls; 450 infants exposed to serotype III GBS at birth - but who do not develop invasive GBS disease in the first 90 days of life from six countries (Malawi, Uganda, UK, the Netherlands, Italy and France).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To establish a biobank of at least 150 GBS serotype III cases including both the isolate and associated maternal and infant serum.	Biobank at St George's, University of London	Over the course of 2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To determine the quantity of antibody associated with protection against GBS disease	Geometric mean and median antibody titres will be calculated for cases and controls and comparisons made as appropriate	Over the course of 2 years
To determine the functional antibody associated with protection against GBS disease.	Samples will be tested using opsonophagocytosis killing assay for both anti-capsular and anti-protein antibodies.	Over the course of 2 years
To demonstrate the relationship between antibody quantity and function in protection against GBS disease	To directly compare total antibody concentration titers (measured by multiplex LUMINEX) with opsonophagocytosis from functional antibodies at the time of birth and at the time of disease.	Over the course of 2 years
To refine estimates for serocorrelates of protection against GBS disease.	To provide initial data on the relationship between antibody and invasive GBS disease risk by estimating the odds ratio of invasive GBS disease for antibody concentrations above various thresholds for STIII	Over the course of 2 years
To provide training to participating African laboratories to assure the quality of sample collection and data curation.	A South-South partnership between Makerere University John Hopkins Research Collaboration (MUJHU),and Malawi-Liverpool-Wellcome Trust Clinical Research Programme (MLW) to optimise the capacity for conducting clinical trials for maternal immunisation in Sub-Saharan Africa	Over the course of 2 years

Collaborators and Investigators

• Sponsor: St George's, University of London
• Collaborators: Assistance Publique - Hôpitaux de Paris; MRC/UVRI and LSHTM Uganda Research Unit; Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); University of Liverpool; Azienda Ospedaliero-Universitaria di Modena; MU-JHU CARE
• Investigators: Principal Investigator: Kirsty Le Doare, Prof, St George's, University of London; Principal Investigator: Stephen Cose, Dr, MRC/UVRI & LSHTM Uganda Research Unit

Study record dates

Study Major Dates

• Study Start (Actual): April 1, 2020
• Primary Completion (Estimated): March 1, 2024
• Study Completion (Estimated): April 1, 2024

Study Registration Dates

• First Submitted: January 26, 2021
• First Submitted That Met QC Criteria: January 26, 2021
• First Posted (Actual): February 1, 2021

Study Record Updates

• Last Update Posted (Actual): October 26, 2023
• Last Update Submitted That Met QC Criteria: October 24, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Systemic Inflammatory Response Syndrome; Inflammation; Disease Attributes; Infant, Newborn, Diseases; Bacterial Infections; Bacterial Infections and Mycoses; Gram-Positive Bacterial Infections; Sepsis; Infections; Communicable Diseases; Streptococcal Infections; Neonatal Sepsis
• Other Study ID Numbers: 17.0021

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No